Novartis Adds New Patent to Curium Fight Over Cancer Drug

Novartis AG units filed a new lawsuit expanding their clash with Curium Pharma subsidiaries over a proposed cancer therapy that would rival their Lutathera injection.

Advanced Accelerator Applications USA Inc. and Advanced Accelerator Applications SA—known as ADACAP—market Lutathera, a targeted cancer therapy for certain rare tumors in the digestive tract. Curium’s branded drug—which uses a US Food and Drug Administration process that allows companies to rely on existing data from previously approved medicines—infringes US Patent No. 12,415,003, according to a complaint docketed Wednesday in the US District Court for the District of Delaware.

The patent, issued Sept. 16, covers ...